Podcasts about mfn

The future of market access belongs to organizations that plan years in advance. In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, explains why pharmaceutical companies must prepare now for major market access changes coming in Europe and beyond. He highlights that Joint Clinical Assessments for rare disease assets, beginning in 2028, will require earlier planning, stronger governance, and more integrated evidence-generation strategies. Steve also discusses the complexity created by varying country-specific care pathways, limited comparators, and the growing importance of real-world evidence in rare disease development. Across policy shifts like JCA, IRA, MFN, and new European pharmaceutical legislation, the central message is clear: organizations that anticipate earlier will be better positioned to succeed. Tune in to hear how the future of rare disease market access is being reshaped, and why companies that prepare earlier will have a major strategic advantage! Resources: Connect with and follow Steve Mather on LinkedIn. Follow Lumanity on LinkedIn and explore their website! Learn more about this series we're doing with Lumanity here:  https://lumanity.com/commercialization-podcasts/

The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC's Global Healthcare Conference, Hunter Hammond and Will Humphrey of Capstone's healthcare group offered insights on the direction of policy for the rest of the year and beyond. Key PointsMandatory Most Favored Nation pricing rules are likely to be contested in court.The FDA's initiatives to speed drug development are signals of its modernization intent.The U.S. is more likely to use incentives than sanctions to address mass in-licensing of Chinese innovation.The current program to extend access to GLP-1s could be a template for future breakthrough drugs.Democrat gains in the midterm elections would likely limit further hospital cuts.Introductions [00:08]Host Joe Coletti introduces highlights from the U.S. Healthcare Policy Panel at RBC's Global Healthcare Conference, featuring Hunter Hammond and Will Humphrey of Capstone's Healthcare Group. Midterm campaigning [00:40]In the run-up to the midterms, the U.S. administration will aim to focus on messaging about popular policies, such as cutting waste and fraud in Medicare and Medicaid.FDA changes [01:41]After turmoil in the FDA, new leadership is designed to promote stability. Recent moves to speed drug approvals are likely to continue and offer an important signal about FDA modernization. Chinese innovation [04:31]The administration may be uncomfortable with U.S. in-licensing of Chinese technologies, but it is more likely to respond with incentives than any attempt to block the practice.Drug pricing [06:17]Most Favored Nation mandatory pricing models have yet to be finalized and are likely to be challenged in court. Democrats will not support codification of MFN.Democrat priorities [08:08]Democratic gains in the midterms would have the effect of protecting hospitals from further cuts. Reform of 340B is unlikely, however.

Life sciences is a hub of dealmaking activity. Over the past year, more than 30 transactions valued at $1 billion or more have crossed the finish line. But the picture in other segments of healthcare is more mixed. At RBC Capital Markets' Global Healthcare Conference in New York, Darren Campili, Global Head of Healthcare Investment Banking, hosts colleagues David Levin, Ahmed Attia and Jason Levitz to explore what's driving deals and where the opportunities are heading.Key PointsHealthcare M&A is strong, with a surge of high-value deals in life sciences.Equity performance is challenging, but investors in life sciences and biotech have seen good outcomes.IPO activity has rebounded; again, life sciences and biotech are most successful.Dealmaking has been largely unaffected by regulatory uncertainty, though challenges remain on reimbursement and MFN pricing.Larger companies believe they have the edge in using AI for profitability and competitiveness.Introductions [00:25]Host Darren Campili, Global Head of Healthcare Investment Banking, introduces the podcast and guests: David Levin, Co-Head of U.S. M&A; Ahmed Attia, Managing Director, Healthcare M&A; and Jason Levitz, Head of Healthcare Equity Capital Markets.M&A strength in healthcare [01:11]The M&A market in life sciences is extremely strong. The number of $1 billion-plus deals has tripled in the past year. There has been significant activity among mid-caps as well as large-cap companies, and a diversity of premiums.Healthcare in the equity markets [13:24]In the broader context of the U.S. equity markets, healthcare is performing poorly, particularly among large-cap medtech and services companies. At the same time, life sciences and biotechs are outperforming, leading to diverse outcomes for investors.IPO activity [15:20]IPO volumes have rebounded after some disappointing years. Deal flow has centered on oncology, I&I, and CNS.Political impact [24:15]Dealmaking has continued despite uncertainty over the FDA. Tariff policy has been a net positive for U.S. inflows as pharma businesses seek U.S. capabilities. Managing reimbursement and Most Favored Nation pricing remains challenging for some.

Life sciences is a hub of dealmaking activity. Over the past year, more than 30 transactions valued at $1 billion or more have crossed the finish line. But the picture in other segments of healthcare is more mixed. At RBC Capital Markets' Global Healthcare Conference in New York, Darren Campili, Global Head of Healthcare Investment Banking, hosts colleagues David Levin, Ahmed Attia and Jason Levitz to explore what's driving deals and where the opportunities are heading.Key PointsHealthcare M&A is strong, with a surge of high-value deals in life sciences.Equity performance is challenging, but investors in life sciences and biotech have seen good outcomes.IPO activity has rebounded; again, life sciences and biotech are most successful.Dealmaking has been largely unaffected by regulatory uncertainty, though challenges remain on reimbursement and MFN pricing.Larger companies believe they have the edge in using AI for profitability and competitiveness.Introductions [00:25]Host Darren Campili, Global Head of Healthcare Investment Banking, introduces the podcast and guests: David Levin, Co-Head of U.S. M&A; Ahmed Attia, Managing Director, Healthcare M&A; and Jason Levitz, Head of Healthcare Equity Capital Markets.M&A strength in healthcare [01:11]The M&A market in life sciences is extremely strong. The number of $1 billion-plus deals has tripled in the past year. There has been significant activity among mid-caps as well as large-cap companies, and a diversity of premiums.Healthcare in the equity markets [13:24]In the broader context of the U.S. equity markets, healthcare is performing poorly, particularly among large-cap medtech and services companies. At the same time, life sciences and biotechs are outperforming, leading to diverse outcomes for investors.IPO activity [15:20]IPO volumes have rebounded after some disappointing years. Deal flow has centered on oncology, I&I, and CNS.Political impact [24:15]Dealmaking has continued despite uncertainty over the FDA. Tariff policy has been a net positive for U.S. inflows as pharma businesses seek U.S. capabilities. Managing reimbursement and Most Favored Nation pricing remains challenging for some.

In Episode 136 of DC EKG, Joe Grogan hosts Tom Barker, a top drug-pricing attorney at Foley Hoag and former acting general counsel of Health and Human Services (HHS) under the Bush administration. Tom helped implement Medicare Part D and now advises drugmakers and policymakers on complex pricing issues. The episode traces 20 years of policy: what went right with Part D, what the Inflation Reduction Act (IRA) did, and what effective policy should look like.Tom explains that Part D's success rested on three pillars: private plans only, limited government control over benefit design, and a non-interference clause barring the government from intervening in negotiations among plans, pharmacies, and manufacturers. Competition worked and premiums stayed low, until the government asserted more control and weakened those pillars. The IRA, he argues, was a 16-year Democratic effort to repeal non-interference, creating price controls disguised as negotiations.The Trump administration has taken a different tack, focusing not on the IRA but on MFN and Globe Guard models pegged to other developed countries. Tom also breaks down the 340B program, now the country's second-largest expenditure program, and the fight between manufacturers and covered entities over contract pharmacies.His prescription is simple: let competition work. Speed FDA approval of generics and biosimilars, and trust the marketplace over price controls. He points to hepatitis C, where prices fell sharply once competition entered.In This ConversationThe three pillars that made Part D successful for 20 yearsHow non-interference kept government from setting drug pricesThe IRA as a 16-year Democratic push to repeal non-interferenceWhy Tom calls the IRA price controls disguised as negotiationsThe Trump administration's focus on MFN and Globe Guard pricing340B and the battle between manufacturers and covered entitiesThe Chevron repeal's impact on drug pricing lawHRSA's proposed rebate model and ongoing 340B litigationWhy effective policy means competition, not controlsTom's work helping North Korean defectors and refugeesKey Timestamps1:51 Tom's background at HHS and CMS2:30 The three pillars of Part D's success5:10 Why Democrats wanted to repeal non-interference5:55 Ted Kennedy's compromise and bipartisan votes11:38 The IRA as a 16-year repeal attempt12:03 What the IRA changed in Part D15:02 IRA negotiations vs. real negotiations16:25 How the excise tax makes it no real negotiation21:32 Trump's focus on MFN and Globe Guard25:37 340B's history back to 199128:45 340B as the second-biggest expenditure program29:30 Manufacturer vs. covered-entity acrimony33:18 The Chevron repeal's impact on pricing34:54 HRSA's rebate model, the next step on 340B35:40 The lawsuit over "patient" in 340B38:18 Tom's advice: let competition work39:30 Hepatitis C: competition drives prices down40:34 Competition for gene therapies and CRISPR41:36 Tom's work for North Korean defectors44:49 Sponsoring Free North Korea RadioMedicare Part D, drug pricing policy, Inflation Reduction Act, non-interference clause, 340B program, MFN pricing, Globe Guard pricing, pharmacy benefit managers, covered entities, contract pharmacies, biosimilars, generics, federal drug pricing, government price controls, Tom BarkerAbout the GuestTom Barker is a partner at Foley Hoag in Washington, DC, and one of the country's top drug pricing attorneys. He served as acting general counsel of HHS and chief legal officer at CMS under the Bush administration, where he helped implement Part D from its inception. He is now a go-to expert on drug pricing, and helps North Korean defectors navigate US immigration law.Podcast: DC EKG with Joe Grogan Episode: 136 Guest: Tom Barker Sponsor: Survivors for Solutions - https://survivorsforsolutions.org Executive Producer: John "CZ" Czwartacki, DC EKG Podcast Producer: Stay on Course Studios - https://www.stayoncourse.studio

Summer is almost here! Rev. Michelle Favreault, Ministerial Formation Network (MFN) Manager, is here to lift-up MFN summer programming and beyond.The Ministerial Formation Network (MFN) is a program of the Unitarian Universalist Ministers Association (UUMA). The MFN can be accessed through the UUMA website: https://www.uuma.org. MFN materials are for UUMA members only, so a login will be required.On Saturday, June 6 there's the MFN Formation Conversation - Introduction to the Summer UU Wellspring cohort REGISTER HERE - If I were to offer one bit of collegial advice it would be to find and dedicate your heart to a small group. We need each other in this work and UUWellspring is a particularly beautiful way to build meaningful relationships.Then, coming up next week on June 9 is the MFN Formation Conversation: Let's Talk! Time with the Ministerial Fellowship Committee REGISTER HEREThe MFN Mosaic Program for Aspirtants and Candidates - a series of 6 sessions to foster belonging and liberation - has only a few spots still available for the program launching in August. You can find out more and REGISTER HERE. ____________________Thank you for listening. Many Windows: Conversations on Ministry is a production of Meadville Lombard Theological School. Theme music is “Destination” by Justhea. This episode is produced by Jules Taylor.(Justhea: spoti.fi/2NycVfd and apple.co/3u51z2V)

Vi hälsar Ola tillbaka till podden med en extra stark tablå. Först blir det en hel del hänt sedan sist (11:35). Sedan bolagen för dagen; Bouvet (62:00); Kitron (73:25); Hexpol (86:50); Veteranpolen (101:20) samt slutligen intervjun med Incaps VD Otto Pukk (148:30). Välkomna! Affärsvärldens fina erbjudande hittar ni här: https://prenumerera.affarsvarlden.se/prenumerera/kvalitetsaktiepoddenKavaljer hittar ni på: www.kavaljer.seHoldings finns på: https://www.modularfinance.se/holdingsBörsdata finns på: www.Borsdata.se Länk till info-sida om Enterprise: https://borsdata.se/info/enterprise/enterpriseLänk till instruktionsvideo: https://www.youtube.com/watch?v=9VPMRTBndkowww.MFN.se har stenkoll på bolagens kommunikation och viktiga datumLäs mer om Läkare utan gränsers verksamhet här: https://lakareutangranser.se/Nästa avsnitt släpps torsdagen den 18 juni Hosted on Acast. See acast.com/privacy for more information.

Angel Academy Session 5 brings in Brian Dirkmaat, a startup attorney at Procopio and longtime SDAC sponsor, to walk the room through the legal mechanics of angel investing. Brian covers the full evolution of startup investment instruments - from the original bridge notes of the 1990s to today's post-money SAFEs - and breaks down the real differences between convertible notes, SAFEs, and priced equity rounds. The session goes deep on valuation caps, pro rata rights, the unresolved IRS question around QSBS treatment for SAFEs, and the practical tradeoffs between investing directly into a company versus through an SPV. If you've ever looked at a term sheet and wondered what you were actually signing, this is the session.Key Topics* The evolution from bridge notes to convertible notes to SAFEs* How YC's post-money SAFE works: valuation caps, discounts, and MFN provisions* SAFE vs. convertible note: the unresolved IRS code 1202 (QSBS) question* Priced equity rounds: Series Seed vs. Series A (NVCA docs)* SPVs vs. direct investing: platforms, carry, admin fees, and when each makes sense* The California C Corp trap: unpaid founder wages and W-2 classification* Term sheet fundamentals: liquidation preferences, anti-dilution, board seatsLinks & Resources* San Diego Angel Conference (SDAC)* Procopio* YC SAFE Documents* NVCA Model Legal Documents* Rising Tide PartnersConnect on LinkedIn* Brian Dirkmaat* Neal Bloom This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit risingtidepartners.substack.com/subscribe

In this episode, we interview Stephen Ubl, President and CEO of PhRMA, to discuss what is happening across the industry at a time of significant change. We talk about biopharma’s continued commitment to innovation, what member companies are doing to help patients access medicines more directly, and how new tools from the organization are supporting patient affordability. We also cover the impact of policies like the IRA and MFN, along with the growing focus on PBM reform and other structural challenges in the system. It is a wide-ranging conversation about where the industry is headed and what it will take to ensure the country continues to lead the world in bringing new treatments to patients in need. Steve Ubl, CEO of PhRMA PhRMA PhRMA Leadership Transition PhRMA 3 Announcements Medicine Assistance Tool (MAT) America’s Medicines Jim Collins, Building Companies to Last FTC Settlement with Express Scripts IQVIA Data: Prior Authorization and Associated Delays and Denials of Branded Medication Dispensation Most Favored Nation Drug Pricing 340B Drug Pricing Program New York Times: How a Hospital Chain Used a Poor Neighborhood to Turn Huge Profits Hatch-Waxman Act Questions or comments?Email us at comments@prescriptionforbetteraccess.com.Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportunities amid the tumult. In many cases, they’re finding that the resilient business models they built through disruptions like the pandemic have positioned their companies not just to survive, but to thrive in a new normal for the industry. In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner chats with Glenn Hunzinger, PwC’s U.S. health industries leader, about results from the firm’s recent survey on investor sentiment. Focusing on health companies, Hunzinger explains how many innovative drugmakers have managed to capitalize on the shifting environment. Still, he warns that a more uncertain landscape for U.S. innovation and continued tariff pressures on sectors such as medtech could pose challenges down the line. To learn more about the topics in this episode: AstraZeneca CEO's conservative MFN model excludes reference markets from forecast As Johnson & Johnson navigates changing tariff landscape, execs lay out their expectations Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg See omnystudio.com/listener for privacy information.

Na Moneyflix, o nosso foco sempre foi o longo prazo, a análise de negócios e a paciência. Então, porquê gravar um episódio sobre trading? Porque o trading, quando feito com método, estômago e gestão de risco, não é o casino que pintam por aí, é uma ferramenta de gestão ativa e uma fonte de rendimento estruturada.Neste episódio, saímos da nossa zona de conforto (e do nosso estúdio!) para receber o Bernardo e o Bruno, fundadores da Air Trading. Vamos rasgar as ilusões do "dinheiro fácil" e mostrar a realidade de quem trabalha os mercados todos os dias.O que vais ouvir nesta conversa:Investimento vs. Trading: Porque é que a tese de longo prazo e o swing trading são aliados perfeitos numa carteira diversificada, em vez de inimigos.O Fim das Ilusões: A verdade crua sobre os "gurus dos Lamborghinis" e por que razão a tua mentalidade e disciplina valem mil vezes mais do que o teu capital inicial.Gestão de Risco: Porque é que aceitar uma perda controlada é a principal característica de quem sobrevive e ganha dinheiro nos mercados.A Grande Novidade: O anúncio oficial da entrada da Air Trading para o ecossistema da comunidade Moneyflix!

In this best-of edition of the Vital Health Podcast, we revisit two conversations Duane Schulthess has with experts on the future of generic medicines, drug shortages, and supply chain risk in the United States. Patrick Kelly: Chief Advocacy Officer, Healthcare Distribution Alliance John Murphy: President and CEO, Association for Accessible Medicines Across these conversations, they discuss how low prices, thin margins, supply chain disruption, reshoring pressure, biosimilar market dynamics, insurance design, and federal pricing policy shape access to generic and biosimilar medicines. Key Topics: Generic Economics: Low prices, thin margins, purchaser pressure, manufacturer exits. Shortage Drivers: Demand spikes, facility shutdowns, sterile injectables, chemotherapy disruptions. Tariffs and Reshoring: Domestic production costs, national security concerns, tariff pass-through, contract constraints. Biosimilar Competition: Private-label programs, vertical integration, investment uncertainty, patient access. Policy and Insurance: IRA redesign, MFN pricing, direct-to-consumer pathways, prescription benefit reform. Opinions expressed are those of the speakers. Original podcasts published in October 2025. The Vital Health Podcast is a production of Vital Transformation LLC © 2026.See omnystudio.com/listener for privacy information.

After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration’s import tariff policy for drugs. While many of the industry’s biggest firms have navigated the trade threat through investment pledges and drug pricing deals, the current landscape remains murkier for small- and mid-sized drugmakers. In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner sits down with Chris Young, a principal in KPMG’s trade and customs practice, to discuss the pharma tariff landscape following President Donald Trump’s announcement in early April of a potential 100% tariff on imported drugs. Young explains how the policy could affect smaller drugmakers that haven’t inked high-profile pricing deals with the government and shares best practices for navigating the rapidly evolving U.S. trade environment. To learn more about the topics in this episode: An update on the pharma industry’s reshoring effort Trump eyes 100% tariff rate for companies that have not struck MFN deals: Bloomberg Trump's tariff threats, measured by manufacturing UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments See omnystudio.com/listener for privacy information.

Hänt sedan sist kan ni ta del av från (05:40). Bolagen för dagen är CAG Group (24:25); Loomis (67:14); Pandora (81:25); Royal Unibrew (95:30) samt Thule (121:00). Välkomna! Affärsvärldens fina erbjudande hittar ni här: https://prenumerera.affarsvarlden.se/prenumerera/kvalitetsaktiepoddenKavaljer hittar ni på: www.kavaljer.seHoldings finns på: https://www.modularfinance.se/holdingsBörsdata finns på: www.Borsdata.sewww.MFN.se har stenkoll på bolagens kommunikation och viktiga datumLäs mer om Läkare utan gränsers verksamhet här: https://lakareutangranser.se/Marknadens avsnitt om AIhttps://podcasts.apple.com/se/podcast/future-shock-agentsv%C3%A4rmar-och-slutet-p%C3%A5-point-and/id1449599682?i=1000760265712 Olles krönikahttps://www.placera.se/kronika/qvarnstrom-sa-kan-ai-sabotera-din-overavkastning-2026-04-10?utm_source=rule&utm_medium=email&utm_campaign=s%C3%A5%20g%C3%A5r%20det%20f%C3%B6r%20investmentbolagen Nästa avsnitt släpps torsdagen den 28 maj Hosted on Acast. See acast.com/privacy for more information.

On this episode of The AIE Podcast… We have a WoW Mini Raid Wrap-up! Lots of patches in lots of games Happy First Contact to all who celebrate And, Happy Birthday to LOTRO! We are chatting amongst ourselves today All that and more coming up right now… Podcast Audio Raw Video http://youtu.be/fvUn580cqSQ Open Welcome to episode # 443 of the podcast celebrating you, the Alea Iacta Est gaming community, the die has been podcast. This is Mkallah: To my left is Mewkow: – (catch phrase here). And to my right is Tetsemi: (catch phrase here). This week we are filling you in on everything going on with AIE. Welcome! Ok, we'll be chatting amongst ourselves shortly, but first, let's cover this week's news… AIE News Community Mandatory Fun Nights Where the fun is mandatory but the attendance is not. Sunday – Destiny 2 8:30 pm Eastern Monday – GW2 9:30 pm Eastern Monday – STO 10:00 pm Eastern Tuesday – SWTOR 9:00 pm Eastern Wednesday – HFO Mythic+ Mayhem (WoW) 8:00 pm Eastern Friday – ESO 9:00 pm Eastern Saturday – LotRO 8:30 pm Eastern Saturday – FFXIV (Maps) 9:30 pm Eastern Saturday – Noob Raid (WoW) 11:00 pm Eastern Streaming and Guild Podcast News We have a ton of AIE member podcasts! Want to know where to find them? Look no further than here- New Overlords Podcast (Max and Sema) https://www.newoverlords.com Boards and Swords (Chris and Philip) https://boardsandswords.com/blog?category=Boards%20%26%20Swords Dr. Gameology ( Dr. Daniel Kaufmann ) https://drgameology.com/ STO – Fleet Action Report (Grebog and Nikodas) https://www.youtube.com/@fleetactionreport A Podcast Reborn: A FFXIV Community Podcast (Brandon aka Old Man Franks, Meagan, and Rho) – NSFL https://www.bonusroll.gg/directory/a-podcast-reborn/ NOMADS New World • Will be sunset in January 2027 • Might do a going away party before it goes away D4 • New expansion this month WoW We have a WoW mini raid wrap up! In Raid Team news, Alliance Team Hell Froze Over (HFO) defeated final boss Crown of the Cosmos (aka Xalatath) in The Voidspire – a victory with unexpected consequences – and then Beloren, first boss in March on Quel’Danas, both on Normal difficulty. On Horde side, Raid Team Kiddie Aggro is now 6/9 in Heroic Voidspire, having out punched the Double Dragons and then sending the Lightblinded Paladin trio bubble hearthing to the Shadowlands. Noob Raid completed the first three bosses in The Voidspire on Normal, and Dankinia’s death count is up to 11. Tetsemi- The next patch for Midnight arrives April 21, bringing new World content such as Void Assaults in Eversong Woods and Zul’Aman as well as Decor Duels – a Hide and Seek challenge that players will queue for. It’s also a busy time for WoW Holidays. Noblegarden ends April 13, Children’s Week arrives April 27 – which may be awkward as Outland orphan Salandria is now an adult NPC in Silvermoon – and Volunteer Guard Duty takes place April 28. Player Housing Endeavors have reset. Fortuna now has Mechagnomes (with miscalibrated hens that jump on your head), Salus has Drakthyr, and Virtus has Ethereals. Consortium won the Alliance side vote. Horde-Fortuna has Mechagnomes. Both got flashy zappy decor rewards this season. And, Gusty is running around with malfunctioning mechachickens on her head. SWTOR In swtor, the guild has some special plans coming for May the 4th, including a trivia contest and a community event. Stay tuned to discord for dates and times. The current Galactic Season is bringing back 2 of the original companions, so if you missed them from GS1 and GS3, now is your chance. MFN is on Tuesdays and everyone is welcome. We promise no more talk about peeps or the proper pronunciation of Coruscant! ESO MFN on Friday still happens, but the group is small FFXIV Next Liveletter is 4/17 North American Fanfest from 4/24-4/25 New major story patch at the end of the month (4/28) STO Lots of stuff going on with STO! All Platforms: Empersa Lance Updates: Damage output reduced, self-damage increased First Contact Day Celebrations! April 7th to May 7th 20 days of progress to earn the grand prize: Nobel Intel Batlecruiser Lobi Sale April 7th to April 12th 20% off all items! Bonus Marks Event April 10th to April 14th 50% bonus for all content that rewards marks For PC- Gral Class command Scout added to Infinity Lock Box starting April 7th Key Sale 15% off Keys from April 7th to April 12th Key Ring Bundle returns as well Includes ultimate tech upgrade LOTRO Lotro is turning 19!!!!! The new gifts will arrive on April 23, with the anniversary event running from April 23 at 10am eastern through May 11. There has been a letter from Orion with an updated development schedule for quarters 2 and 3 of this year. Some of the highlights arriving in the near future is new content with update 48 “A Glorious Hunt” as well as Rivendell Housing. A link to the letter is in the lotro channel. Also Saturday Night Lotro will kick back off this coming Saturday after an unexpected hiatus. And with that, let's see what we have been doing in and out of game GAME NEWS CLOSE And that's our show for tonight. While the chatroom begins suggesting show titles, we want to thank us for joining us. If you have a question or comment about our show, you can email us at podcast@aie-guild.org You can find us on the AIE Discord and BlueSky https://bsky.app/profile/aiepodcast.bsky.social. We record live with video once a month on Sunday at 8pm Eastern/5pm Pacific. You can join the chatroom and play along with us on our website at https://aie-guild.org/podcast-live-stream/ and look for the link to our discord server at https://aie-guild.org. And for past episodes, you can see them on our Youtube channel, https://www.youtube.com/c/TheAIEPodcast ! Our theme was composed by the amazing Andrew Allen, follow him at @keyswithsoul! And now it's time to play all of the great AIE member segments we received this week, including… Next time, we'll be talking to Guest in Game. So until then, AIE… – This is Mkallah – This is Mewkow – This is Tetsemi

Europe does not lack talent. It does not lack scientists. What it often lacks is structure.Welcome to Pharma Minds, Mini-Series « Who controls innovation ? ». In this series, we explore one question in two parts: who controls innovation - and who actually makes it happen.There is an alarming gap in global healthcare: more than 100 new drugs currently available in the United States are still not accessible to European patients. Why?  Because while Europe produces exceptional research, its access pathways are fragmented, and increasingly influenced by global pricing debates such as Most Favored Nation (MFN) policies.In this episode, we tackle the execution gap with Pierre-Henri Belin, Co-Founder and CEO of Xcube.Bio. His company accelerates biopharma market entry across Europe by mitigating risks and bridging the gap between capital, deep expertise, and industry knowledge. Pierre-Henri shares a bold vision to pool resources, make Europe attractive for research again, and ensure that innovation actually reaches the people who need it.Because research without access is only half a success.In this episode, we cover:◾️ The 100-Drug Gap: The alarming disparity between US and European patient access to new treatments.◾️ The Root Causes: How fragmented regulatory systems and national-level decision-making are holding Europe back.◾️ The Consequences: What this delay means for patients and the global competitiveness of Europe's healthcare ecosystem.◾️ The Solution: Pierre-Henri's proposed model built on transparency, early collaboration, and shared responsibility.◾️ A Path Forward: How Europe can reinvent its system and become a more predictable market without sacrificing safety or trust.If Europe wants to remain a scientific leader, it must restructure. But this raises a deeper question: is the pharmaceutical economic model still aligned with the expectations of public health systems?

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Melanie Whittington, Managing Director and Head of the Leerink Center for Pharmacoeconomics and Senior Fellow at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center. They examine how health economic modeling can more accurately reflect real-world market dynamics, the rising pressure behind IRA and MFN drug pricing, the risks to oncology innovation, the limits of conventional cost-effectiveness frameworks, plus the role of transparency and clearer communication of long-term value in sustaining a healthy innovation ecosystem. Key Topics Market Modeling: Hypothetical models versus real-world pricing dynamics, patent cliffs. Pricing Policy: IRA, MFN, market-based pricing scrutiny, communicating why prices are "worth it". Innovation Incentives: Private capital risk, oncology small molecules, policy-driven pipeline shifts. Value Framework Limits: QALY concerns, rule-versus-tool debates, GRACE, broader treatment impacts. Transparency and Outlook: Net price opacity, PBM negotiations, generics and biosimilars, the next innovation cycle. Opinions expressed are those of the speakers. The Leerink Center for Pharmacoeconomics is a division of MEDACorp.See omnystudio.com/listener for privacy information.

Send us Fan MailWhat if paying less for your prescriptions was not just possible, but predictable? Speaking of Women's Health Podcast host Dr. Holly Thacker walks us through a clear, six-step playbook to cut medication costs without cutting corners, drawing on years of women's health practice, patient stories, and the latest programs reshaping access and pricing.Dr. Thacker shares how to use discount cards and price comparison sites to uncover true cash prices in your zip code, when to skip insurance at the counter, and how 30- versus 90-day fills change your bottom line. She highlights new manufacturer pathways—direct discounts, MFN-priced listings, and printable coupons—that bring branded therapies back within reach, plus practical tips for navigating supply hiccups and keeping a smart buffer on hand.Throughout, Dr. Thacker keeps two goals in view: better health and a saner budget. You'll leave with a checklist you can act on today—compare prices, verify manufacturer offers, coordinate with your insurer, optimize dose, and diversify sourcing—plus long-term moves like using an HSA and scheduling preventive care to avoid last-minute spikes. If this helped you save, subscribe, leave a quick review, and share the episode with someone who needs a lower bill at the pharmacy. Your voice helps more women be strong, be healthy, and be in charge.Support the show

Read our MFN preprint: https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/ In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two Vital Transformation colleagues on biopharma pricing policy, market access, and innovation risk: Gwen O'Loughlin: Research Partner at Vital Transformation Harry Bowen: Consulting Economist at Vital Transformation They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation. Key Topics: MFN Modeling: Net present value analysis, benchmark-country pricing, launch viability, and market uncertainty. Effects of IRA on Trials: Oncology pullback, small-molecule exposure, orphan drug pressure, and suspended trials. Coverage Friction: Medicare Advantage burden, prior authorization delays, formulary shifts, and referral slowdowns. 340B Transparency: Vertical integration, hospital consolidation, opaque pricing flows, and revenue pressure. Innovation Outlook: Premium increases, global competition, intellectual property risk, and future access concerns. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

I detta avsnitt är ordningen återställd och alla tre musketörerna är åter på plats i studion. Hänt sedan sist kan ni ta del av från (24:00). Bolagen för dagen är New Wave (05:45); Nolato (64:46); Gofore (78:40); Inission (92:00) samt intervjun med Rejlers VD Viktor Svensson (104:00). Välkomna! Affärsvärldens fina erbjudande hittar ni här: https://prenumerera.affarsvarlden.se/prenumerera/kvalitetsaktiepoddenKavaljer hittar ni på: www.kavaljer.seHoldings finns på: https://www.modularfinance.se/holdingsBörsdata finns på: www.Borsdata.sewww.MFN.se har stenkoll på bolagens kommunikation och viktiga datumLäs mer om Läkare utan gränsers verksamhet här: https://lakareutangranser.se/Citrinis rapporthttps://www.citriniresearch.com/p/2028gicHesten genomgång av Turkiethttps://www.casinofeber.se/media/turkiet-kraftsamlar-mot-illegalt-spel-hur-kan-det-sla-mot-betsson Nästa avsnitt släpps torsdagen den 23 april. Hosted on Acast. See acast.com/privacy for more information.

After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury's analysts discuss how the company has built a pipeline and set of enabling technologies that could enable a steep period of value creation based on RNAi.The team then analyzes the $2 billion deal between Synnovation and Novartis for a pan-mutant-selective PI3Kα inhibitor. The analysts also assess where AI is integrating into the biotech venture funnel and provide insights into ultra-rare disease advocacy, FDA's search for a successor to CBER Director Vinay Prasad, and the Trump administration's most-favored nation (MFN) drug pricing policy.View full story: https://www.biocentury.com/article/658892#RNAiTherapeutics #BiotechMA #PI3KAlpha #AIDrugDiscovery #DrugPricingPolicy00:00 - Introduction01:14 - Bio€quity Europe05:33 - Arrowhead16:49 - Synnovation Novartis20:00 - AI in Biotech Venture27:07 - Rare Disease Advocacy31:22 - MFN Pricing PolicyTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

On this episode of The AIE Podcast… World of Warcraft is now on Zillow Congrats to Sethos on 70! Spring Abundance is in the air Nifty things are happening in LOTRO And, we have our dear friends Gusty and Shojo here to talk all about AIE in World of Warcraft All that and more coming up right now… Podcast Audio Raw Video http://youtu.be/dWQ9wXpGYyY Open Welcome to episode #442 of the podcast celebrating you, the Alea Iacta Est gaming community, the die has been podcast. This is Mewkow: To my left is Tetsemi: – (catch phrase here). And to my right is Mkallah: (Hey folks, there is a homemade chicken pot pie in the Guild Kitchen). This week we are joined by special guests Gusty and Shojo who are here to talk to us about AIE in World of Warcraft Welcome! Ok, we'll be digging into World of Warcraft shortly, but first, let's cover this week's news… AIE News Community Mandatory Fun Nights Where the fun is mandatory but the attendance is not. Sunday – Destiny 2 8:30 pm Eastern Monday – GW2 9:30 pm Eastern Monday – STO 10:00 pm Eastern Tuesday – SWTOR 9:00 pm Eastern Wednesday – HFO Mythic+ Mayhem (WoW) 8:00 pm Eastern Friday – ESO 9:00 pm Eastern Saturday – LotRO 8:30 pm Eastern Saturday – FFXIV (Maps) 9:30 pm Eastern Saturday – Noob Raid (WoW) 11:00 pm Eastern Streaming and Guild Podcast News We have a ton of AIE member podcasts! Want to know where to find them? Look no further than here- New Overlords Podcast (Max and Sema) https://www.newoverlords.com Boards and Swords (Chris and Philip) https://boardsandswords.com/blog?category=Boards%20%26%20Swords Dr. Gameology ( Dr. Daniel Kaufmann ) https://drgameology.com/ STO – Fleet Action Report (Grebog and Nikodas) https://www.youtube.com/@fleetactionreport A Podcast Reborn: A FFXIV Community Podcast (Brandon aka Old Man Franks, Meagan, and Rho) – NSFL https://www.bonusroll.gg/directory/a-podcast-reborn/ NOMADS Rust on a PvE server since the new naval update came out. Boats are fun! New World will officially shutdown its servers January 31, 2027. We are still there! Keep an eye on the channel in nomads for a possible farewell as the end draws near. Valheim 5 Year Celebration and Regular Update. AIE Valheim Community Server Information is pinned in the AIE Discord #Nomads channel WoW Noob Raid had a great final run of Manaforge Omega on pre-Midnight launch – clearing both Normal and Heroic! Dankinia will be taking a break until the first raid in Midnight is released, around early April. Midnight launched on 3/2, with early access for folks who prepurchased expected to begin 2/27. Lots more about Midnight from our lovely guests later in the show. Player housing. This new feature is time consuming but a great deal of fun. The creativity of our Guildies is amazing to behold! WoW Classic As Jehdai pointed out, we have our first 70 (Sethos) and light activity on the 20th Anniversary TBC launch on Dreamscythed Horde side. We have the guild available with the guild bank open and invite others to join us in Outland. In other Classic news: Reminder that there are now 3 launchers for Classic (‘Original’, ‘Anniversary’, ‘Era’) “Original” Classic is progressing with Mists of Pandaria. The guild is available on Horde side on Galakras. If I have this right, MoP classic uses the modern guild interface so we have the new interface showing 651 members. “Anniversary” Classic which is now at TBC as mentioned above. “Era” classic is a separate launcher with 3 game modes: ‘Classic Era’ which is forever frozen in the original game (pre-TBC). We were on Mankrik here but really no activity or guild. “Season of Discovery” which is where experiments were performed by the devs which some expect may lead to the anticipated “Classic Plus” many hope for. We have no real activity there currently. “Hardcore” is the 3rd game mode in the Era client and probably our 2nd most active within the classic modes. We have an Alliance side guild on Doomhowl and some activity on the Horde side of Doomhowl but no guild currently. Lars plans to return to his attempt at a “Solo Self-Found” run to 60 in Hardcore but that has been on pause for quite some time. We did have guild members make it to 60 on the hardcore server previously. Ravisant is ProffessorWC or Sethos one of the raid leaders from HoG SWTOR In Swtor this week, we are ready for Update 7.8.1, Master’s Enigma. It will bring a story piece, Galactic Seasons 10, new date nights, and the Spring Abundance Festival. The story finale is coming in the June timeframe to make room for 8.0 at the end of the year. We continue to do our MFN on Tuesday nights. Please join us. There are no gear or level requirements, but you may need to have gotten your personal ship as we do tend to travel about. If you want to read about an awesome trip to Galaxy’s Edge, with not only pics but also tips and tricks for your own visit, check out guildie Strykezone’s blog post. You’ll find a link in the pinned messages in the swtor channel of the AIE discord. The Kanjiklub House https://kanjiklubhouse.com/2026/02/18/my-star-wars-adventure-to-galaxys-edge-at-disney/ ESO The guild has been working on endeavors and in game events. FFXIV This past Tuesday we got the new Variant dungeon with the newer middle level difficulty The next live letter is on March 13th at 4am PST, and they'll probably be discussing the next story patch LOTRO We had an update that brought us some nifty things. The new raid “The Folly of Nagakhêdi” (Nah-gah-KAY-dee) for tier 1 is live, tiers 2 and 3 are coming this week and next week. There is a new legendary reward track with some great rewards such as a rose-colored mûmak calf cosmetic pet. With other class changes, mainly with guardian, we also got a great change. It is now possible to start Private Encounters from inside of a Housing Neighborhood. Looking forward to seeing you in game and doing some of these awesome new instances. And with that, let's get back to Gusty and Shojo and find out what's going on in World of Warcraft. GAME NEWS CLOSE And that's our show for tonight. While the chatroom begins suggesting show titles, we want to thank Gusty and Shojo for joining us. If you have a question or comment about our show, you can email us at podcast@aie-guild.org You can find us on the AIE Discord and BlueSky https://bsky.app/profile/aiepodcast.bsky.social. We record live with video once a month on Sunday at 8pm Eastern/5pm Pacific. You can join the chatroom and play along with us on our website at https://aie-guild.org/podcast-live-stream/ and look for the link to our discord server at https://aie-guild.org. And for past episodes, you can see them on our Youtube channel, https://www.youtube.com/c/TheAIEPodcast ! Our theme was composed by the amazing Andrew Allen, follow him at @keyswithsoul! Next time, we'll be talking to Guest in Game. So until then, AIE… – This is Gusty – This is Shojo – This is Mewkow – This is Tetsemi – This is Mkallah And this has been… The AIE Podcast

Audio roundup of selected biopharma industry content from Scrip over the business week ended Mar.6, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB's big China deal. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-N3WEPHD34BHGBGRM5BNJPTS2NY/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury's analysts assess what the deal does for the Foster City, Calif.-based biotech's pipeline.The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week's PhRMA Forum, which focused on China and the Trump administration's most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA's about-face on the recent vaccine application from Moderna.View full story: https://www.biocentury.com/article/658516#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA00:00 - Introduction02:34 - Gilead's Arcellx Buy11:14 - ctDNA Surrogate Endpoints21:59 - PhRMA Forum Takeaways29:19 - FDA Moderna U-turnTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Slowly but surely – and just in time for the State of the Union – the full picture of the Trump Administration's Most-Favoured Nations drug pricing policy is coming into focus. At the end of last year, CMS published the draft guidance for its GLOBE and GUARD pricing models, which establish MFN pricing in Medicare Part B and Part D, respectively. And earlier this month TrumpRx – the government's promised patient-facing discount portal – finally went live. On today's podcast, Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert, to break down what we know and what we still don't know about each of these developments. Among other things, Valder Curran breaks down how the two CMS pilot programmes will work, what statutory authority CMS is leaning on (and whether that authority is likely to be challenged), and how the industry is responding. Comstock and Valder Curran also discuss TrumpRx and how impactful it's shaping up to be, at least based on what's been revealed so far. And how do those negotiated MFN deals fit in to all this? We can't give you the answers to all your questions about MFN – too much is still up in the air. But this podcast will at least give you an idea of what those open questions are and how they're likely to play out. You can listen to episode 246 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Host: Cindy Allen Published: February 20, 2026 Length: ~18 minutes Presented by: Global Training Center Summary “Tariff Friday” may go down as one of the most pivotal days in recent trade history. In this episode of Simply Trade: Cindy's Version, Cindy Allen breaks down the U.S. Supreme Court's 6–3 decision ruling that IEEPA does not authorize the President to impose tariffs. The Court found that the authority to levy taxes and tariffs belongs to Congress, and that the term “regulate” under IEEPA does not include the power to raise revenue. Inspired by Taylor Swift's Opalite, Cindy walks through what the ruling actually says, what it does not say, and what importers and customs brokers should do right now while awaiting further instruction from the Court of International Trade (CIT) and CBP. The decision may have brought sunlight—but operational clarity will take time. This Week in Trade (Before the Ruling) • Awaiting details on Taiwan 15% MFN (or higher) structure • Pending clarification on India IEEPA reciprocal adjustment (25% to 18%) • Indonesia agreement announced with 19% tariff and textile tariff-rate quota • No movement on elimination of First Sale • No further action on ending IEEPA on Canada • U.S. manufacturing indicators down; stock market up The Supreme Court Decision The Supreme Court issued a 6–3 opinion finding that IEEPA does not grant authority to impose tariffs. Key findings: • IEEPA contains nine enumerated action verbs — none include taxing or raising revenue • Congress alone holds the constitutional authority to levy tariffs • Specific delegated authorities (Sections 301, 232, 122, 338) include limitations and procedural controls • Because Congress created these specific tariff authorities, a broad IEEPA tariff authority cannot be implied • During peacetime, the President does not have independent tariff authority The Court remanded the case back to the lower court — likely the U.S. Court of International Trade (CIT) — which must now issue implementation instructions. What We Still Don't Know • When the CIT will issue instructions • When (or if) CBP will suspend IEEPA tariff collection • Whether refunds will be automatic or require action • Whether de minimis is affected • Whether related trade agreements tied to IEEPA remain intact • Whether the administration pivots to Section 122 or 338 authorities What Importers Should Do Right Now Cindy's recommendation is clear: Continue paying duties until formal CBP guidance is issued. Why? • Duties were in effect at time of entry • Monthly statement entries could otherwise be considered unpaid • CBP systems still contain IEEPA tariff numbers and edit checks • Programming updates will take time Stopping payment prematurely could create compliance risk. Refunds, when issued, will likely require formal action — potentially protests, post-summary corrections, or other ACE updates. Given the volume of entries involved, automatic refunds appear unlikely. Key Takeaways • IEEPA tariffs have been ruled unlawful for revenue purposes • Congress retains sole tariff authority • Operational changes will depend on CIT and CBP implementation • Continue paying duties until official guidance is issued • Refund mechanics remain unclear • Trade professionals must remain disciplined and patient Resources & Mentions • Global Training Center • TradeForce Multiplier • U.S. Supreme Court Opinion (24-1287) Credits Host: • Cindy Allen – LinkedIn • TradeForce Multiplier Producer: • Lalo Solorzano – LinkedIn Subscribe & Follow New episodes every Friday. Presented by Global Training Center — providing education, consulting, workshops, and compliance resources for trade professionals. • Simply Trade Podcast on LinkedIn • Global Training Center on LinkedIn • YouTube • Spotify • Apple Podcasts • Trade Geeks Community

Arunima Sinha, from the U.S. and Global Economics team, discusses how an upcoming Supreme Court decision could reshape consumer prices, retail margins and the inflation outlook in 2026.Read more insights from Morgan Stanley.----- Transcript -----Arunima Sinha: Welcome to Thoughts on the Market. I'm Arunima Sinha from Morgan Stanley's U.S. and Global Economics Teams.Today: How a single Supreme Court ruling could change the tariff math for U.S. consumers.It's Friday, February 13th at 10am in New York.The U.S. Supreme Court is deciding whether the U.S. president has legal authority to impose sweeping tariffs under IEEPA. That decision could come as soon as next Friday. IEEPA, or the International Emergency Economic Powers Act, is the legal backbone for a significant share of today's consumer goods tariffs. If the Supreme Court limits how it can be used, tariffs on many everyday items could fall quickly – affecting prices on the shelf, margins for retailers, and the broader inflation outlook.As of now, effective tariff rates on consumer goods are running about 15 percent, and that's based on late 2025 November data. And that's quite a bit higher than the roughly 10 percent average, which we're seeing as tariffs on all goods. In a post IEEPA scenario, we think that the effective tariff rate on consumer goods could fall to the mid-11 percent range.It's not zero, but it is meaningfully lower.An important caveat is that this is not going to be eliminating all tariffs. Other trade tools – like Section 232s, which are the national security tariffs, Section 301s, the tariffs that are related to unfair trade practices – would remain in place. Autos and metals, for example, are largely outside the IEEPA discussion.The main pressure point we think is consumer goods. IEEPA has been used for two major sets of tariffs. The fentanyl-related tariffs on Mexico, Canada, and China, and the so-called reciprocal tariffs applied broadly across trading partners. And these often stack on top of the existing tariffs, such as the MFN, the Most Favored Nation rates, and the section 301 duties on China that were already existing before 2025.The exposure is really concentrated in certain categories of consumer goods. So, for example, in apparel and footwear, about 60 percent of the applied tariffs are IEEPA related. For furniture and home improvement, it's over 70 percent. For toys, games, and sporting equipment, it's more than 90 percent. So, if the IEEPA authority is curtailed, the category level effects would be meaningful.There are caveats, of course. The court's decision may not be all or nothing. And policymakers could turn to alternative authorities. One example is Section 122, which allows across the board tariffs for up to 15 percent for 150 days. So, tariffs could just reappear under different tools. But in the near term, fully replacing IEEPA-based tariffs on consumer goods may not be straightforward, especially given ongoing affordability concerns.So, how does that matter for the real economy? There are two key channels, prices and margins. On prices we estimate that about 60 percent of the tariff costs are typically passed on to the consumers over two to three quarters, but it's not instant. Margins though could respond faster. If companies get cost relief before they adjust prices downwards, that creates a temporary margin tailwind. That could influence hiring, investment and earnings across retail and consumer supply chains.Over time, lower tariffs could also reinforce that broader return to core goods disinflation starting in the second quarter of this year. And because tariff driven inflation has weighed more heavily on the middle- and lower-income households, any eventual price relief could disproportionately benefit those groups.At the end of the day, this isn't just a legal story. It is a timing story. If IEEPA authority is curtailed, the arithmetic shifts pretty quickly. Margins move first, prices follow later, and the path back to goods disinflation could accelerate. That's why this is one ruling worth watching before the gavel drops.Thanks for listening. If you enjoy the show, please leave us a review wherever you listen and share thoughts on the market with a friend or colleague today.

Host: Cindy Allen Show: Simply Trade – Cindy's Version Published: February 13, 2026 Length: ~15 minutes Presented by: Global Training Center State of Grace: Tariffs, First Sale Under Fire, and a Glimmer of Stability In this episode of Cindy's Version, Cindy Allen, CEO of TradeForce Multiplier, walks through another busy week in global trade and ties it to Taylor Swift's “State of Grace”—focusing on the idea that, despite the shock of recent policy shifts, this is still a “worthwhile fight” for trade professionals. From new trade deals to challenges against tariff policy and first sale threats, Cindy explains what's changing and where there are signs of hope.​ What You'll Learn in This Episode New trade deals and tariff shifts A U.S.–Taiwan deal capping total tariffs at 15% (either limiting MFN above 15% or applying 15% where MFN is lower). Details emerging on agreements with Guatemala, El Salvador, Argentina, and an India deal rolling back some reciprocal tariffs tied to India's Russian oil purchases.​ Where to find official text and specifics: USTR's website.​ Border infrastructure and electronic bonds The administration's threat to block the opening of the long‑planned Gordie Howe Bridge between Detroit and Ontario over funding/ownership disputes, and why Canada and Michigan intend to proceed regardless. How this new public crossing will compete with the privately owned Ambassador Bridge for billions in daily cross‑border trade.​ CBP's move to mandate electronic surety bond filing for all bonds, formalizing what many brokers, importers, and sureties already do—and why Cindy strongly supports it.​ Section 232 guidance softens (slightly) New CBP guidance on 232 tariffs for steel, aluminum, and copper, dialing back earlier aggressive interpretations. Trade groups have received written clarification allowing certain labor/overhead costs to be prorated into steel/aluminum values instead of fully loaded, even as petitioners continue to argue that none of those costs should be included. Why importers should review the latest guidance carefully, track affected entries, and monitor the ongoing Court of International Trade challenge.​ USMCA and IEPA signals from Capitol Hill Senate Finance Committee signaling support for extending USMCA, seeking stability before any renegotiation, while the administration is rumored to prefer separate bilateral deals with Canada and Mexico.​ The House vote to end IEPA duties on Canada for certain non‑USMCA goods—a positive step toward predictability, though the bill still must clear the Senate and avoid a presidential veto.​ First sale under threat Introduction of a bill to eliminate first sale, driven by some of the same groups that pushed to curtail de minimis and oppose duty‑reducing mechanisms generally. Why this is significant: many large importers rely on first sale, provide extensive upstream data to CBP, and enable deeper supply‑chain visibility and risk management. Trade associations have already begun weighing in to defend first sale; Cindy flags this as a fight to watch closely.​ EU deal conditions and a big auto bill The EU moving its U.S. tariff deal through lawmakers but adding elements like sunset deadlines and “security triggers” that go beyond earlier negotiating language.​ Ford announcing an expected 900 million dollar 232‑related tariff hit after previously anticipated automotive offsets were disallowed for several months—raising questions about how other automakers will fare and whether Ford might push back through protests or litigation.​ Global trade up, U.S. trade down Conference insights from Manifest: global trade volumes are rising overall, but trade into the U.S. is declining, as exporters pivot to other markets they perceive as less costly and less complex. This trend aligns with a surge in trade deals worldwide that do not include the U.S.​ Why “State of Grace”? Cindy connects the week's developments to Taylor Swift's “State of Grace,” highlighting the line: “I never saw you coming and I'll never be the same. This is a state of grace, this is a worthwhile fight.” She uses this to frame: How studies now confirm what many suspected—U.S. consumers have already paid roughly 1,000 dollars more due to tariffs, with an additional 1,300 dollars expected in the coming year. How tariffs are hitting companies and rural communities: constrained exports for U.S. agriculture, rising small‑farm bankruptcies, and knock‑on impacts to local economies. Research showing that about 90% of tariff costs are passed from suppliers to U.S. importers, then to consumers, and even to manufacturers who never import directly but rely on tariff‑burdened inputs.​ Despite this, she sees reasons for cautious optimism: Companies challenging IEPA and 232 in court. Large players like Ford publicly quantifying tariff impacts. Congress beginning to reassert its constitutional role over tariffs and question security‑based justifications used as broad economic tools. Early, coordinated pushback against eliminating first sale—stronger than what was seen around de minimis.​ For Cindy, these developments suggest the industry may be entering a state of grace—a moment where data, legal challenges, and coordinated advocacy start to rebalance the conversation and make the fight for smarter trade policy worth it.​ Credits Host: Cindy Allen Producer: Annik Sobing Presented by: Global Training Center Sponsor: PAX AI ​ Listen & Subscribe Simply Trade main page: https://simplytrade.podbean.com​ Apple Podcasts: https://podcasts.apple.com/us/podcast/simply-trade/id1640329690​ Spotify: https://open.spotify.com/show/09m199JO6fuNumbcrHTkGq​ Amazon Music: https://music.amazon.com/podcasts/8de7d7fa-38e0-41b2-bad3-b8a3c5dc4cda/simply-trade​ Connect with Simply Trade Podcast page: https://www.globaltrainingcenter.com/simply-trade-podcast​ LinkedIn: https://www.linkedin.com/showcase/simply-trade-podcast​ YouTube: https://www.youtube.com/@SimplyTradePod​ Join the Trade Geeks Community Trade Geeks (by Global Training Center): https://globaltrainingcenter.com/trade-geeks/

While only about 13% of the nation's population is Black, the percentage of incarcerated Blacks can be as high as 50 %. The proportion of Black men on death row is significantly higher than that of whites.Our guest, Courtney Teasley, a criminal defense lawyer, emphasizes the responsibility that defense attorneys have in contributing to incarceration rates. Some lawyers fail to communicate with clients, push plea deals without proper consultation, and neglect to use available court resources or file necessary motions.This lack of diligence can result in missed opportunities for discovering evidence that could change the outcome of a trial. Courtney stresses that defense lawyers should fight for their clients and not simply “go along to get along,” especially in smaller counties where maintaining good relationships with judges is common practice.Courtney described the DAMM community—Disproportionately Affected Marginalized Minority—as the primary demographic impacted by incarceration. Systemic factors such as inadequate education in financial literacy, criminal justice literacy, and civics contribute to this problem. Many individuals are not taught their rights or how to hold government officials accountable, nor are they given the tools to pursue financial stability beyond low-wage jobs.These gaps leave people vulnerable to crimes of poverty and ill-equipped to navigate the legal system if accused. Having financial means, legal knowledge, and civic understanding provides leverage and empowerment, but these advantages are often unavailable in marginalized communities.Courtney's initiatives focus on legal literacy, financial literacy, and civics. She teaches these subjects through mock trial programs at high-priority schools and at HBCUs, aiming to address the lack of foundational legal knowledge. Her business, MFN, stands for Mindset, Finesse, and Non-Negotiable Boundaries, and is dedicated to advocacy training and lawyer coaching.Courtney also discussed the school-to-prison pipeline, which refers to the disproportionate punishment of Black students in schools, which leads to higher rates of suspension and disciplinary actions that can lead to the juvenile justice system.She advocates for empowering students through education in legal literacy, civics, and financial skills, noting that access to such knowledge and opportunities is often limited. Programs and curricula she develops aim to bridge these gaps and provide students with tools for legal and financial empowerment.Ultimately, the need for competent, passionate lawyers in criminal defense is critical. The goal is not necessarily to achieve acquittals for all clients, but to ensure the state proves its case and to minimize negative impacts on individuals' records and communities. Creative solutions, rehabilitation, and strategic partnerships are encouraged to address root causes of crime and support long-term positive outcomes.

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Tim Scott, President & CEO of Biocom California, a biopharma executive with more than two decades of experience, including spinning out companies from UC San Diego and leading firms acquired by BioMarin and Novartis, to discuss how California’s life sciences ecosystem became a global innovation engine, why the state’s research and venture networks matter, and how policy headwinds such as the Inflation Reduction Act (IRA) and Most Favored Nation (MFN) reference pricing reshape investment, rare disease development, and competition with Europe and China. Key Topics: Biocom Origins: Municipal policy roots, industry advocacy, ecosystem evolution across California. Innovation Network: University and research density, regional clusters, talent, and collaboration effects. Capital Pathway: NIH and NSF support, SBIR and STTR bridges, venture appetite, and liquidity. MFN and IRA: Pill penalty incentives, orphan exemption stakes, Medicare exposure, and VC pullback. Next-Gen Development: AI-enabled discovery, faster trial enrollment, digital twins, and regulator openness. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

On this week's episode, Josh Schimmer, Sam Fazeli, Brian Skorney, and Yaron Werber kick off with a discussion on policy with special guest BIO's CEO John Crowley, overviewing what it means for the U.S. to “win” the biotech race against China, emphasizing the need for innovation and ensuring access to medicines. The conversation shifts to the latest at the FDA, where John acknowledges concerns around consistency at the agency and expresses optimism following conversations with FDA leadership at the JP Morgan Healthcare conference earlier this month. Next, the co-hosts discuss major investments in China, including AstraZeneca's $15B commitment to China through 2030, focusing on R&D, manufacturing, and partnerships. Shifting back to U.S. policy, the group addresses the growing measles outbreak, highlighting the belief that science, data, and policy pressure will win out over anti-science rhetoric. Next, John notes that codifying MFN would be devastating for the industry. The conversation turns to deals, with Merck's decision not to acquire Revolution Medicines, noting that the company's current strong cash position and recent deals will likely make them attractive to Big Pharma in the future. Next, Eikon Therapeutics' planned $273.5M IPO is also highlighted. The episode concludes with an overview of the FDA's clinical hold on a Regenxbio gene therapy and discussion on Amgen stepping away from its OX40 partnership. *This episode aired on January 30, 2026.

 In Episode 123 of DC EKG, Joe Grogan sits down with Jackson Hammond (Senior Policy Analyst, Paragon Health Institute) to unpack what the latest CMS National Health Expenditure (NHE) data says about where U.S. health care is headed. They break down the June 2025 NHE release, compare it to Jackson's earlier “Paragon Prognosis” analysis, and explain what changed, what didn't, and what it means for affordability, Medicare, Medicaid, and long-run fiscal pressure. They also connect the spending outlook to Jackson's paper, “How to Reform the CMS Innovation Center with a Choice and Competition Approach,” and debate whether CMMI is bending the cost curve or just adding bureaucracy without accountability. Jackson argues we should aim for health care so affordable you barely need insurance. Chapters / Timestamps  00:00 – Intro + welcome  00:55 – Jackson's background: how he got into health policy  03:39 – Focus areas: Medicare, hospitals, drug pricing, PBMs, 340B  05:14 – What the NHE report is showing  06:14 – $5.2T → $5.6T → $8.6T: why the trajectory matters  08:00 – Why health spending isn't really “optional”  10:11 – Where the money is going: payer mix + per-enrollee costs  12:23 – Medicaid costs, provider taxes, and state financing tactics  15:58 – Medicare spending pressure and fiscal risk  21:06 – Misconception: “coverage = care”  26:18 – Why provider payments keep rising (post-COVID demand + consolidation)  33:01 – Rural care, consolidation, and the REH / hub-and-spoke model  40:08 – Drug pricing: retrospective vs prospective MFN  49:20 – 2026 outlook + closing thanks In This Conversation  • NHE 2025: what the June 2025 data confirms about spending growth and the federal share.  • Rising prices, flat health: why prices climb while outcomes lag.  • Medicare and Medicaid: why they remain major budget drivers.  • Coverage vs access: why an insurance card doesn't guarantee care or better health.  • Hospitals and consolidation: what's driving higher payments and fewer choices.  • Rural vs urban: why patients bypass local hospitals and what a better model could look like.  • Drug pricing: what MFN approaches might mean for costs and innovation.  • 2026: what Jackson expects next and what reform could realistically look like. Key Takeaways  • NHE data points to continued, unsustainable spending growth.  • Medicare and Medicaid drive long-term budget pressure.  • Consolidation and payment incentives shape prices as much as utilization.  • CMMI reform hinges on accountability, choice, and competition.  • Smarter drug pricing policy should lower costs without undermining innovation. About Our Guest  Jackson Hammond is a Senior Policy Analyst at the Paragon Health Institute focused on health spending, CMS policy, and reforms centered on choice, competition, and patient-centered care. He authors Paragon's “Paragon Prognosis” analyses and wrote “How to Reform the CMS Innovation Center with a Choice and Competition Approach.”

 In Episode 123 of DC EKG, Joe Grogan sits down with Jackson Hammond (Senior Policy Analyst, Paragon Health Institute) to unpack what the latest CMS National Health Expenditure (NHE) data says about where U.S. health care is headed. They break down the June 2025 NHE release, compare it to Jackson's earlier “Paragon Prognosis” analysis, and explain what changed, what didn't, and what it means for affordability, Medicare, Medicaid, and long-run fiscal pressure. They also connect the spending outlook to Jackson's paper, “How to Reform the CMS Innovation Center with a Choice and Competition Approach,” and debate whether CMMI is bending the cost curve or just adding bureaucracy without accountability. Jackson argues we should aim for health care so affordable you barely need insurance. Chapters / Timestamps  00:00 – Intro + welcome  00:55 – Jackson's background: how he got into health policy  03:39 – Focus areas: Medicare, hospitals, drug pricing, PBMs, 340B  05:14 – What the NHE report is showing  06:14 – $5.2T → $5.6T → $8.6T: why the trajectory matters  08:00 – Why health spending isn't really “optional”  10:11 – Where the money is going: payer mix + per-enrollee costs  12:23 – Medicaid costs, provider taxes, and state financing tactics  15:58 – Medicare spending pressure and fiscal risk  21:06 – Misconception: “coverage = care”  26:18 – Why provider payments keep rising (post-COVID demand + consolidation)  33:01 – Rural care, consolidation, and the REH / hub-and-spoke model  40:08 – Drug pricing: retrospective vs prospective MFN  49:20 – 2026 outlook + closing thanks In This Conversation  • NHE 2025: what the June 2025 data confirms about spending growth and the federal share.  • Rising prices, flat health: why prices climb while outcomes lag.  • Medicare and Medicaid: why they remain major budget drivers.  • Coverage vs access: why an insurance card doesn't guarantee care or better health.  • Hospitals and consolidation: what's driving higher payments and fewer choices.  • Rural vs urban: why patients bypass local hospitals and what a better model could look like.  • Drug pricing: what MFN approaches might mean for costs and innovation.  • 2026: what Jackson expects next and what reform could realistically look like. Key Takeaways  • NHE data points to continued, unsustainable spending growth.  • Medicare and Medicaid drive long-term budget pressure.  • Consolidation and payment incentives shape prices as much as utilization.  • CMMI reform hinges on accountability, choice, and competition.  • Smarter drug pricing policy should lower costs without undermining innovation. About Our Guest  Jackson Hammond is a Senior Policy Analyst at the Paragon Health Institute focused on health spending, CMS policy, and reforms centered on choice, competition, and patient-centered care. He authors Paragon's “Paragon Prognosis” analyses and wrote “How to Reform the CMS Innovation Center with a Choice and Competition Approach.”

Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Senior Biopharma Analyst Danielle Golovin's four-part analysis of how next-generation targeting chimeras (TACs) are evolving. The analysts assess the $2.2 billion takeout of Rapt Therapeutics by GSK, which gave the pharma an allergy asset that the biotech sourced in China in 2024, and movement in Washington on priority review vouchers, NIH's budget and the White House's “most favored nation” drug pricing policy. The analysts also discuss takeaways from their meetings on the sidelines of the J.P. Morgan Healthcare Conference.View full story: https://www.biocentury.com/article/658112#InducedProximity #TargetingChimeras #BiotechMA #DrugPricingPolicy #JPMHealthcare00:00 - Introduction 03:17 - JPM Highlights09:17 - GSK's Acquisition of RAPT14:46 - Next-Generation Targeting Chimeras21:41 - MFN and Pediatric PRVsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation (MFN) drug pricing and its knock-on effects for jobs, state budgets, and the generic supply chain. Over the past year, proposals to link U.S. prices to those in other countries have collided with inflation pressures, tariff debates, and reshoring efforts, creating new uncertainty for manufacturers, payers, and policymakers. In an environment where expectations about future returns are shifting, and the rules of the game are still being defined, this episode is designed as a year-end guide to what MFN-style policies could mean in practice and how to think about the tradeoffs. Throughout 2025, we our research on MFN-style reference pricing with a series of podcast episodes where host Duane Schulthess sat down with leaders across the generic, distribution, and policy landscape. In this highlights episode, we revisit several of those conversations: Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks Patrick Kelly: Inside the Generic Supply Chain Squeeze John Murphy: Generics, Biosimilars, and U.S. Policy VT’s Grumpies (Harry Bowen, Joe Hammang) Talk MFN Key Topics: MFN Mechanics Explained: How tying U.S. prices to the lowest GDP-adjusted price in a reference basket translates into steep cuts for top-spend medicines in Medicare Parts B and D and shapes expectations across commercial and Medicaid contracts. Jobs, Earnings, & State Budgets: What our modeling suggests about potential impacts on employment, earnings, and tax revenue under MFN-style reference pricing, and how those effects concentrate in R&D-intensive regions and manufacturing hubs. Spillovers Into Medicaid, 340B, & ASP: Why MFN in Medicare does not stay in Medicare, how Medicaid best price and 340B ceilings pull discounts across programs, and what lower ASP add-ons could mean for hospital and community oncology margins. Generics, Shortages, & Tariffs: How razor-thin margins for sterile injectables and generic manufacturers interact with purchaser consolidation, tariff shocks, and price referencing, raising the risk of exits, inventory write-downs, and persistent shortages. Global Competition & Offshoring: How aggressive reference pricing can accelerate shifts in trials, licensing, and high-value manufacturing to countries that offer more predictable returns, and what that implies for long-run U.S. competitiveness. Alternatives To MFN: Ideas from our guests on value-based approaches, targeted incentives, and other tools that can improve affordability without hollowing out domestic capacity, innovation, and resilience in the generic and biosimilar supply chain. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

Crypto funding rounds often look glamorous from the outside: big name investors, big valuations, big narratives. But behind the scenes, the terms can look very different — and sometimes, radically so. In this episode of Bits + Bips, host Steve Ehrlich sits down with reporter Jack Kubinec, who broke the story about Berachain's Series B and one of the most unusual terms we've seen in a major token deal: a lead investor receiving the right to ask for its entire $25 million investment back, for up to a year after Berachain's token launched. Jack walks through what the documents show, why lawyers say the clause is extremely rare, and how a refund right like this could impact other investors, and even trigger MFN clauses. They also unpack Berachain's market struggles since TGE, the state of the Nova Digital fund inside Brevan Howard, and the transparency questions this episode raises across crypto venture investing. Read the full story here on Unchained Thank you to our sponsor Uniswap!  Host: Steve Ehrlich, Executive Editor at Unchained Guest: Jack Kubinec, Crypto Journalist and Podcast Host Timestamps: 0:00 — Start 0:25 — Steve introduces Jack 2:24 — What the documents reveal 5:17 — Why Brevan Howard's refund is a big problem 9:21 — How refund clauses really work 14:09 — Jack's interactions with the Bera team and how Smokey responded to the story 19:29 — Why the MFN clause is key 26:19 — How Breva Howard Digital didn't actually invest in Bera 30:18 — What investors should learn from a deal like this Learn more about your ad choices. Visit megaphone.fm/adchoices

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

Audio roundup of selected biopharma industry content from Scrip over the business week ended November 1, 2025. In this episode: Pfizer's unwavering pursuit of Metsera; Lilly's obesity momentum; Merck & Co.'s MFN negotiations; Novartis's promising Sjögren's results; and the rising Chinese pressure on US innovation. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-2K33BM6BLBDU7JH7QMETUXUKPE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA's entry into the drug pricing fray. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott and counsel Monica Groat explore the voucher awards in detail and discuss how the accelerated review period might affect launch strategies, whether companies with no voucher will be disadvantaged, and potential risks and concerns. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

Arthur Wong examines AbbVie (ABBV) following the healthcare company's earnings beat in its 3Q. He discusses the pharmaceutical pipeline, its oncology segment and current offerings like its autoimmune medication Humira. Arthur discusses the relationship between weaker consumer sentiment and patients willingness to spend on expensive medical treatments. He also talks about the industry trend to negotiate lower drug-costs with the Trump administration. He says tariffs and "MFN" Pricing (Most Favored Nation) are the biggest headwinds for pharmaceutical companies.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

In this episode, Audrey sits down with registered dietitian and founder of Nourished by Taylor, Taylor Lechner, to talk about what really happens when you've been on birth control for 10+ years and decide you're done. They get into why so many women lose their period, come off the pill, and suddenly have acne, anxiety, mood swings, gut issues, or no ovulation — and why it's not just “your hormones being crazy.” Taylor breaks down post–birth control syndrome, the labs she runs (HTMA, gut, minerals, thyroid), how copper and mineral depletion play into PMS and anxiety, and why testing > guessing. If you're thinking about coming off the pill/implant/IUD — whether or not you want to get pregnant — this is the one to listen to.Connect with Taylor:Taylor has a free gift for you all!!! :  Breakup with Birth Control MasterclassIG: nourishedbytayWebsite: https://nourished-by-taylor.com/Taylor Lechner, MFN, RD, LD, is a Registered Dietitian and founder of Nourished by Taylor. She helps women transition off birth control, heal acne, mood swings, and achieve symptom-free cycles with a root-cause approach. Her mission is to help women feel understood, empowered, and no longer dismissed with “that's just part of being a woman."  ✨✨ RISE Tribe - Next Steps✨✨Join us for RISE: The Happiness Summit - for free! - https://www.helloaudreyrose.com/risehappy 11:11 Sound Bath - www.helloaudreyrose.com/1111FREE 7 day Nervous System Reset Group - get daily nervous system reset practices in just 10 min a day, with Audrey as your guide https://www.helloaudreyrose.com/7days Nervous System Reset Training (Free): www.helloaudreyrose.com/reset RISE Sisterhood (private membership for nervous system regulation + spiritual alignment) www.helloaudreyrose.com/sisterhood 

Our U.S. Biotech and Biopharma analysts Sean Laaman and Terence Flynn discuss the latest developments that could be positioning the healthcare sector for strong outperformance.Read more insights from Morgan Stanley.----- Transcript -----Sean Laaman: Welcome to Thoughts on the Market. I'm Sean Laaman, Morgan Stanley's U.S. Small and Mid-Cap Biotech Analyst. Terence Flynn: And I'm Terence Flynn, Morgan Stanley's U.S. Biopharma Analyst. Sean Laaman: Today, we'll discuss how a rally in the healthcare sector is being driven by more favorable macro conditions. It's Tuesday, October 28th at 10am in New York. So, Terence, healthcare has lagged the broader market year-to-date, and valuations have been near historical lows. But recent weeks show strengthening performance. Policy headwinds have been front and center.What's changed in the regulatory environment and how is the biopharma sector adapting to these pricing and tariff dynamics? Terence Flynn: Sean, as you know, with many other sectors, tariffs were initially a focus earlier this year. But a number of companies in our space have subsequently announced significant U.S. manufacturing investments to reshore supply chains. And hence, the market's less focused on tariffs in our space right now. But the other policy dynamic and focus is what's called Most Favored Nation or MFN drug pricing. Now, this is where the President's been focused on aligning U.S. drug prices with those in other developed countries. And recently we've seen several companies announce agreements with the administration along these lines, which importantly has provided investors with more visibility here. And we're watching to see if additional agreements get announced. Sean Laaman: Got it. Another hurdle for Large-cap biopharma is a looming expiration of patents with [$]177 billion exposed by 2030. How is this shaping M&A trends and strategic priorities? Terence Flynn: For sure. I mean, as you know, Sean, patent expiry is our normal part of the life cycle of drug development. Every company goes through this at some point, but this does put the focus on company's internal pipelines to continue to progress while also being able to access external innovation via M&A. Recently we have started to see a pickup in deal activity, which could bode well for performance in SMID-cap biotech. Sean Laaman: At the same time, you believe relative valuations look compelling for Large-cap biopharma. Where are valuations versus where they've been historically? What's driving this and how should investors think about positioning? Terence Flynn: Absolutely. Look, on a price to earnings multiple, the sector's trading at about a 30 percent discount to the S&P 500 right now. Now that's in line with prior periods of policy uncertainty. But as policy visibility improves, we expect the focus will shift back to fundamentals. Now, positioning to me still feels light here, given some of the patent cliff dynamics we just discussed. Now, Sean, with the Fed moving toward rate cuts, how do you see this impacting your sector on the biotech side? Sean Laaman: Well, Terence, particularly in my space, which is Small- and Mid-cap biotech companies, they're typically capital consumers are not capital producers. They're particularly sensitive to the current rate environment.Therefore, they're sensitive to spending on pipeline. They're sensitive to M&A. So, as rates come down, we expect more spending on pipeline and more M&A activity, which is generally positive for the sector. Looking forward, biotech sector is generally the best performing sector on a six-to-12-month timeframe post the first rate cut. Terence Flynn: Great. You've also talked about this SMID to Big thesis on the biotech side. Can you explain what's driving that? Sean Laaman: Sure Terence. There's three pieces to the SMID to Big thematic. So, we in SMID-cap biotech, we cover 80 to 90 companies. About a third of those are newly, kind of profitable companies. Those companies are turning from being capital consumers to capital producers. We see about $15 billion of cash on balance sheets for 2025, going to north of 130 billion by 2030. That's the first piece. The second piece is due to regulatory uncertainty at the USFDA. We're seeing more attractive valuations amongst clinical stage names. That's the second piece. And third piece relates to your coverage, Terence. I refer back to that [$]177 billion of LOE. So, we expect generally that M&A activity will be quite high amongst our sector. Terence Flynn: And let's not forget about AI, which has implications across the healthcare space. How much is this changing the dynamic in biotech, Sean? Sean Laaman: It is changing, but we're really at the beginning. I think there's three things to think about. The first one is faster trial recruitment. The second one is faster regulatory submissions. And the third one, which is the most interesting, but we're really at the beginning of, is faster time to appropriately targeted molecules. Terence Flynn: Great. And maybe lastly, what are the key risks and catalysts for SMID-cap biotech in the current environment? Sean Laaman: As always, we're focused on pipeline failures in terms of risk. Secondly, in terms of risk, we're looking at regulatory risk at the FDA. And thirdly, we're looking at the rise in China biotech and the competitive dynamic there.Whether you're watching large cap biopharma, M&A moves, or the rise of cash-rich, SMID-cap biotechs, the healthcare sector setup is unlike anything we've seen in years.Terence, thanks for speaking with me. Terence Flynn: Always a pleasure to be on the show. Thanks for having me, Sean. Sean Laaman: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

In this episode, Greg and Rob chat about what the government shutdown might mean for 340B Program oversight in the short-term. They'll also discuss a flurry of developments from manufacturers recently. Specifically, they'll highlight efforts to promote more direct-to-consumer (DTC) pathways for obtaining medications, all related to a recent Trump Administration executive order calling for “most favored nation (MFN)” pricing for drugs in the U.S. SpendMend will be at the 340B Grantee Conference in Atlanta October 20 – 22.  Stop by our booth and also catch our presentation at the “Ask the Experts – Open Forum” while you are there!

In this episode, former CMS official Jon Blum reflects on the evolution and impact of the IRA's drug provisions—from foundational drivers and political trade-offs to how 2026 Part D redesign and the M3P cost-smoothing program are reshaping access. We explore why M3P adoption remains limited, how CMS is monitoring plan behavior around negotiated pricing, and what shrinking standalone Part D options may mean for patients, especially in rural areas. Jon also challenges the “blame game” in Washington—emphasizing the systemic incentives behind each actor—and shares his own prescription for equitably balancing drug affordability, innovation, and policy integrity, including thoughts on MFN and future reform paths.

On this episode of The AIE Podcast... The great migration is under way And, we have a mini raid wrap up! Congradullances to Stask! Kdf Recruits incoming And, we are catching up with ourselves All that and more coming up right now... Podcast Audio Raw Video http://youtu.be/BfHzOgkipbI Open Welcome to episode #438 of the podcast celebrating you, the Alea Iacta Est gaming community, the die has been podcast. This is Mkallah: To my left is Tetsemi: - (catch phrase here). And to my right is Mewkow: (catch phrase here). This week we are having a host show Welcome, friends! Ok, we'll be digging into what we have been up to in and out of game shortly, but first, let's cover this week's news... AIE News Community Mandatory Fun Nights Where the fun is mandatory but the attendance is not. Sunday - Destiny 2 8:30 pm Eastern Monday - GW2 9:30 pm Eastern Monday - STO 10:00 pm Eastern Tuesday - SWTOR 9:00 pm Eastern Wednesday - HFO Mythic+ Mayhem (WoW) 8:00 pm Eastern Friday - ESO 9:00 pm Eastern Saturday - LotRO 8:30 pm Eastern Saturday - FFXIV (Maps) 9:30 pm Eastern Saturday - Noob Raid (WoW) 11:00 pm Eastern Streaming and Guild Podcast News We have a ton of AIE member podcasts! Want to know where to find them? Look no further than here- New Overlords Podcast (Max and Sema) https://www.newoverlords.com Boards and Swords (Chris and Philip) https://boardsandswords.com/blog?category=Boards%20%26%20Swords Dr. Gameology ( Dr. Daniel Kaufmann ) https://drgameology.com/ STO - Fleet Action Report (Grebog and Nikodas) https://www.youtube.com/@fleetactionreport A Podcast Reborn: A FFXIV Community Podcast (Brandon aka Old Man Franks, Meagan, and Rho) - NSFL https://www.bonusroll.gg/directory/a-podcast-reborn/ WoW The great migration to the active 5 horde co-guilds is going well. Member removal of accounts that haven't logged in for a year or more also was completed and we have plenty of room for growth, so we kept the two recruiting co-guilds, Libertas and Fortuna, open for another month. The consolidation on the alliance side and culling of accounts also left us with plenty of room for growth. It feels so much better to login and see so many others in guild playing. We encourage those who haven't made the migration to please do so, and don't be shy. If you need help, officers are here for you. We get it, it can be scary to hit the /gquit, but I think you will like rejoining an active co-guild. Alliance side MFN raid team HFO is 7/8 on normal and working on the dance with Demensius. Noob Raid ran Firelands for the Timewalking quest, with thanks to Ashayo for getting a skip on the (again) bugged Lord Rhyolith. Ragnaros was troublesome but we took him down eventually, then hopped over to the new Raid, Manaforge Omega to defeat first boss, Plexis Sentinel on Normal. Kiddie Aggro has feasted upon Nexus King Saladbar and are now 7/8 Heroic in Manaforge Omega. Next stop: Dimensius. Surely our bestie Xal-Atath will reward us well for his demise this time? Raid Team Dungeoneering INC has advanced to 4/8 Heroic with successful kills of Loomithar, Soulbinder and Forgeweaver. Raid team So Let's Go Skating got 3/8 heroic last week with a sub 1% best pull on Araz, they're going back in this evening for revenge! SWTOR AIE in swtor has a new Guild Master! Corley has passed the reigns on to Stask. Show them both some love! ‘Where's the Cantina' Operations Team is hosting a 16 man run of Terror From Beyond on Monday, September 8. For fun times and a Galactic Seasons objective, check in discord for more info and to let Machete know you are interested. There are no gear requirements, but you must be 80 and subbed FFXIV New relic step is out Cosmic Exploration has been updated with a new map to visit, and new rewards to craft and gather for. Map night continues every Saturday at 9:30 pm eastern. Don't be intimidated,

What if your gym could be the first line of defense against chronic disease? In this insightful episode of the Fitness Business Podcast, host Justin 'JT' Tamsett discusses the concept of 'Exercise is Medicine' with expert Lisa Dougherty, who has 27+ years of experience in the field. They explore the significant impact of physical inactivity on global health and the economy, emphasizing the crucial role of tailored exercise in combating chronic diseases. Lisa shares her journey and the evolution of specialized fitness training for various medical conditions. They also discuss best practices for gyms and trainers, the importance of advanced education, and how gyms can build respect within the healthcare continuum. The episode finishes with details on Lisa's upcoming virtual global medical fitness conference, bringing together a wealth of knowledge and expertise for fitness professionals worldwide.  Key highlights from the episode: - A global health wake-up call: Why inactivity is projected to cost $314–$446 billion annually by 2050 and how gyms can position themselves as part of the healthcare solution. - Best practices for “exercise as medicine” programs: Education requirements, record-keeping, safety protocols, and emotional intelligence as core skills. - Business opportunities in medical fitness: How specializing in chronic condition populations can set you apart from competitors and create long-term client loyalty.   Know the SECRET codeword? Submit it here for the chance to win a $100 Amazon Gift Card!* https://www.fitnessbusinesspodcast.com/codeword    Ready for more: - Become an FBP Insider and get 7 days FREE to start! Learn more on Patreon: https://patreon.com/FitnessBusinessPodcast - Our FREE LIVE online events created specifically for fitness business owners, managers, and coaches who want to sharpen their skills and grow their business - Learn More: https://fitnessbusinesspodcast.com/onlineevents - Leave us a voicemail: https://fitnessbusinesspodcast.com/leave-us-a-voicemail/ - Leave a rating on Spotify or Apple Podcasts: https://fitnessbusinesspodcast.com/review/ Quotes: “It is crucial for fitness and allied healthcare professionals working with the aging population to have this higher level of knowledge, skill, and expertise.” - Lisa Dougherty “I started the MFN to improve the quality of life of the many millions of people with chronic disease and medical conditions.” - Lisa Dougherty “The fitness industry still targets the' nearly fit'. Which is, you know, 15% of the population, and those are the shark infested waters. And 85% of the rest of the population has obesity, diabetes, high blood pressure, cardiovascular disease, osteoporosis, cancer…it's a scroll of diseases.” - Lisa Dougherty Resources: - Become an FBP Insider on Patreon: https://patreon.com/FitnessBusinessPodcast - Fitness Business Podcast's LinkedIn Community: https://www.linkedin.com/groups/9878228/ - Mystery Shopping for Fitness Businesses: https://mysteryshoppingforfitnessbusinesses.com.au/    Our Guest: Lisa Dougherty, Medical Fitness Expert Website: https://www.MedFitFoundation.Org LinkedIn: https://www.linkedin.com/in/lisadougherty1/    Event: 2025 Virtual Global Medical Fitness Conference: https://www.fbasucceed.com/medfit Use the Code: FITBIZ to save 25% (case sensitive!)   Sponsor's Pitch: Clint Aragona Max Members AI Website: https://www.maxmembers.ai/Email:clint@maxmembers.ai LinkedIn: https://www.linkedin.com/in/clinten-aragona-470123290/ and https://www.linkedin.com/company/maxmembers   Merch Sponsor: ROGUE - https://www.roguefitness.com/ Be a Merch Sponsor - https://fitnessbusinesspodcast.com/merch/   REX Roundtables: Website: www.REXRoundtables.comEmail: Eddie@REXRoundtables.com   Free Online Live Events: https://fitnessbusinesspodcast.com/onlineevents   REX Roundtables Trusted Suppliers: 1. Reinig Insurance: Ken Insurance Guy specializes in risk management and insurance for fitness businesses https://theinsuranceguy.com/ Power Plate: Whole-body vibration for fitness and wellness - https://powerplate.com/ ROR Partners: offering data-driven marketing strategies to enhance customer relationships. https://rorpartners.com/ HR Network: All your HR needs solved at the end of the phone. https://hrnetworkinc.com/ Referrizer: Automates marketing and referrals for your business https://business.referrizer.com/   About Our Guest: Lisa Dougherty has been in the medical fitness space for over 25 years. She founded the MedFit Network in 2013, which serves as both a professional membership organization and a free online resource directory. She established the MedFit Education Foundation, a nonprofit organization, in 2017 to elevate the quality and quantity of available education for fitness and allied healthcare through educational webinars, online courses, and virtual conferences. Lisa has been recognized as a fitness leader on multiple occasions, including by Personal Fitness Professional Magazine and The Huffington Post. The White House acknowledged her as a “Champion of Change”. About Your Host: Justin "JT" Tamsett is a fitness industry veteran with over 30 years of experience who aims to reduce global healthcare costs by promoting physical activity. Through his company Active Management, he provides business coaching to fitness entrepreneurs, leads 8 REX Roundtables in the US and Australia, and has spoken at over 40 conferences across 23 countries. His ultimate goal is to create a world of opportunity for his daughter Zoe by helping more people move and stay healthy, while empowering gym owners to build successful businesses that contribute to a healthier society   Please note: We only recommend products we care about (affiliate links support our free content). Thank you for your support!

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 22, 2025. In this episode: Madrigal regains MASH lead with EU Rezdiffra approval; Viking's obesity data scare investors; China assets lead GLP-1 deals; CSL and others restructure; and Indegene exec on DTP and MFN policies. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T77LV22VANAL5GNPCC2YUVLZBE/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger Picture The EU folded and they made a deal with the US. The US has the advantage now. Trump admin is putting pressure on Fed Gov Cook to resign. Trump is positioning himself to have the majority in the Fed to vote for a rate cut. The tariffs will begin paying off the debt. Trump is now dismantling the 5th column. We are in the process of taking back the country from the evil tyrants. The [DS] might try a [FF] before the midterms. If they believe they don't have a chance in winning there is a possibility of an event. Trump and the patriot's are expecting this to happen and this is why the NG is being put into place to counter the riots and other events.   Economy https://twitter.com/howardlutnick/status/1958484249406775348 This deal: Eliminates EU tariffs on all U.S. industrial goods, Creates historic access to the vast European markets for American farmers, fishermen and ranchers, Delivers $750B in European energy demand during President Trumps term And EU firms will invest an additional $600B in new investments in America The America First Trade Agenda has secured the most important trading partner creating a major win for American workers, U.S. industries, and our national security. Tariffs should be one of America's favorite words. See the full Joint Statement below (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");   https://twitter.com/KobeissiLetter/status/1958486074885586971   only MFN tariffs on EU aircraft/parts, generics, chemical precursors, and scarce natural resources 4. EU to eliminate tariffs on all US industrial goods and grant preferential access for US seafood/agriculture Energy & Tech Purchases: 1. EU to buy $750B in US LNG, oil, and nuclear products 2. EU to purchase at least $40B in US AI chips Investment & Cooperation: 1. EU firms to invest $600B in US strategic sectors by 2028 2. Both sides to negotiate rules of origin to ensure benefits remain bilateral 3. Exploring cooperation on steel and aluminum market protections 4. Joint commitment to tackle digital trade barriers; EU pledges not to adopt network usage fees 5. Considering measures for secure supply chains, including tariff-rate quota solutions https://twitter.com/HedgieMarkets/status/1958245475704041673   the Fed is using inflation as a gauge for rate cuts, then rate cuts are nowhere near. Core CPI inflation is back above 3.0% and PPI inflation just jumped +0.9% MoM, its biggest jump in 3+ years. That said, the last Fed meeting happened BEFORE the last jobs report. Regardless, today's Fed Minutes were a major blow to the “Fed pivot” camp. Powell appears ready to hold rates steady if he feels it is necessary. The September jobs report will decide everything. https://twitter.com/pulte/status/1958281801023033751 Hypothetically, if she were to step down (or resign) from her position, the President would nominate a replacement to fill the vacancy for the remainder of her unexpired 14-year term. That nominee would then require confirmation by the U.S. Senate before taking office, as outlined in the Federal Reserve Act. This is the standard process for filling vacancies on the seven-member Federal Reserve Board. There are currently six members on the Federal Reserve Board of Governors,

On this episode of The AIE Podcast... We have your Summer of Love schedule With D&D, and Lore, and Remembrance Day, and more Congrats to the SWTOR on a total galactic win Big Changes are coming to LOTRO And, we are chatting amongst ourselves All that and more coming up right now... Podcast Audio Raw Video http://youtu.be/sm6TJ3q-Mj4 Open Welcome to episode #436 of the podcast celebrating you, the Alea Iacta Est gaming community, the die has been podcast. This is Mewkow: To my left is Mkallah: - (Hey, folks, there are fig and goat cheese pinwheels in the guild kitchen). And to my right is Tetsemi: (catch phrase here). This week we have your Summer of Love schedule and other gaming news! Ok, we'll be chatting about what we've been up to shortly, but first, let's cover this week's news... AIE News Community Where the fun is mandatory but the attendance is not. Sunday - Destiny 2 8:30 pm Eastern Monday - GW2 9:30 pm Eastern Monday - STO 10:00 pm Eastern Tuesday - SWTOR 9:00 pm Eastern Wednesday - HFO Mythic+ Mayhem (WoW) 8:00 pm Eastern Thursday- Board Game Night (1st and 3rd Thursdays) 7:00 pm Eastern/6:00 pm Central Friday - ESO 9:00 pm Eastern Saturday - LotRO 8:30 pm Eastern Saturday - FFXIV (Maps) 9:30 pm Eastern Saturday - Noob Raid (WoW) 11:00 pm Eastern Streaming and Guild Podcast News We have a ton of AIE member podcasts! Want to know where to find them? Look no further than here- New Overlords Podcast (Max and Sema) https://www.newoverlords.com Working Class Nerds (Marcus and Nick) - NSFL https://workingclassnerdscom.wordpress.com Boards and Swords (Chris and Philip) https://boardsandswords.com/blog?category=Boards%20%26%20Swords Dr. Gameology ( Dr. Daniel Kaufmann ) https://drgameology.com/ STO - Fleet Action Report (Grebog and Nikodas) https://www.youtube.com/@fleetactionreport A Podcast Reborn: A FFXIV Community Podcast (Brandon aka Old Man Franks, Meagan, and Rho) - NSFL https://www.bonusroll.gg/directory/a-podcast-reborn/ Summer of Love July 26th - August 2nd with August 2nd being Remembrance Day So far Summer of Love will include two D&D one-shots, one hosted by Duskmire in a Star Wars setting and the other hosted by Kraemer for ESO on their MFN night. If anyone is interested in hosting a One-Shot, contact Gustytail. We'll also have Lore Night, where participants will share a story from in game lore, events or their character's backstory. In WoW, we'll have trivia night in Guild chat with pet and transmog giveaways, WoW Hide and Seek, and a Delves event. SWTOR The big news in SWTOR is that we won both our Total Galactic War last week and are using this week to pick prizes, lie on beaches with pina coladas, and not do uprisings for a bit. It was a close race on some days, but we pulled away near the end and our competition just could not catch us. Check out discord for our victory screenshot. And while you are there, feel free to click on the capybara link. It will make your day better. ESO Summer of Love we have the D&D one shot down at the docks going on on our usual MFN Friday August 1st and we will meet at Kini's main house on Saturday August 2nd for Remembrance Day in the Chapel room. FFXIV Come join us for map night at 9:30 eastern every Saturday! As long as you have completed the Heavensward main story there's stuff for you to do! You can even join us as part of the free trial, or if you're in a different FC or world! We're on Goblin in the crystal data center. STO Fleet Action Report, your weekly dive into the world of Star Trek Online! In Episode 257, join hosts Nikodas, Tabbytha, and Grebog as they plunge into the unknown—deep into Fluidic Space itself! This week, they tackle the eerie missions “Assimilation” and “Fluid Dynamics”, where the Borg and Undine collide in one of STO's most unsettling story arcs. What happens when the Borg find a way to assimilate the Undine?

Market Update: Resurgent AI, Market Movements, and Crypto Insights In this episode of Dividend Cafe, Brian Szytel from West Palm Beach discusses recent market trends on a quiet trading day. The S&P 500 saw modest gains, while the Dow was down slightly. Key points include an uptick in AI sector activity driven by policy shifts and supply chain dynamics, significant M&A activity in the utility sector, and a cautious perspective on pharmaceutical pricing changes due to the MFN executive order. Brian also addresses an audience question about cryptocurrency investments, advising on its volatility and practicality in portfolios. Looking ahead, he previews an action-packed economic calendar for the following day. 00:00 Introduction and Market Overview 01:06 AI Sector Resurgence and Policy Shifts 02:10 Utility Sector and Power Generation 02:58 Trade Policies and Sector Impacts 03:29 Pharmaceutical Industry Disruptions 05:27 Upcoming Economic Data and Events 06:02 Cryptocurrency Investment Considerations 08:15 Conclusion and Sign Off Links mentioned in this episode: DividendCafe.com TheBahnsenGroup.com